KYIV. March 22 (Interfax-Ukraine) – Public joint-stock company AvtoKrAZ (Kremenchuk, Poltava region), the only Ukrainian producer of heavy trucks, has acquired YL-20S workshop crimpers from Finland’s D-Hydro to replace nine deteriorated presses at the company.
The deal is part of the upgrade of the tool fleet with the purpose of improving the quality of products.
The company’s press service reported on Monday that the new equipment would enable the company to stop paying for the services of a third-party.
“With the acute shortage of working capital and the austerity measures introduced at the plant due to the financial crisis, it was hard for the plant to allocate these small funds to acquire the crimpers – around UAH 200,000. Thanks to this equipment the plant will improve the quality of high and low pressure tools,” the company spokesman said.
It will take from one and a half or two years to pay back the loan used to buy the equipment.
AvtoKrAZ makes 33 basic vehicle models, and more than 260 modifications and trim levels for civilian and military vehicles.
KYIV. March 22 (Interfax-Ukraine) – Public joint-stock company Carlsberg Ukraine (Zaporizhia), a large brewery in Ukraine, saw a 9.85% rise in net profit in 2015, to UAH 929.085 million.
Over the period net profit totaled UAH 0.9087 per share (the total number of shares is 1.022 billion), compared to UAH 0.8273 per share in 2014.
Undistributed profit reached UAH 2.48 billion as of late 2015.
Current liabilities increased to UAH 1.274 billion from UAH 975.7 million in 2014. The company did not have non-current liabilities.
Total bills receivable shrank by 6.4%, to UAH 634.3 million.
Carlsberg Ukraine is incorporated in Carlsberg Group, a leading brewing groups in the world. Carlsberg Group in Ukraine includes three breweries in Zaporizhia, Kyiv, and Lviv.
KYIV. March 22 (Interfax-Ukraine) – The Ukrainian government has approved a customs clearance procedure for imported goods used in production of defense goods under a state defense order. The goods are exempted from taxation to meet required Customs and Tax codes.
According to the procedure outlined in cabinet resolution No. 170 of March 16, a list of documents required to register imports of these goods is set up to confirm their compliance with concrete criteria.
According to the document, the State Fiscal Service is to submit information on imported goods every quarter to the Economic Development and Trade Ministry. The information is to include the names of economic entities, public procurement authorities and the sum of taxes that were not paid, while executors of the state defense order are to submit monthly reports on the targeted use of the imported goods.
KYIV. March 21 (Interfax-Ukraine) – Public joint-stock company Cherkasy Silk Factory, one of the largest textile enterprises in Ukraine, tentatively saw UAH 35.95 million in net profit in 2015, while its net loss in 2014 was UAH 50,000.
Its uncovered loss decreased by almost 83% in a year, to UAH 7.4 million.
The factory saw a 55% rise in current liabilities, to UAH 91.3 million. The company did not have long-term liabilities.
Total bills receivable tripled, to UAH 36.16 million, while asset value grew by 6.8%, to UAH 191.34 million.
Equity capital exceeded UAH 100 million as of early 2016 (UAH 64 million as of early 2015).
The plant began fabrics production in 1967 and today manufactures lining, raincoat fabric, fabrics for professional clothing, decorative jacquard, furniture, shirting fabric.
Its major markets were Ukraine, Moldova, and Russia.
KYIV. March 21 (Interfax-Ukraine) – Private joint-stock company Indar (Kyiv), an insulin producer, has obtained GMP (Good Manufacturing Practice) certificate for its production facilities in Brazil.
The certificate was issued by the Brazilian Health Surveillance Agency (ANVISA).
A GMP is a system for ensuring that pharmaceutical products are consistently produced and controlled according to quality standards.
Indar supplies recombinant insulin in the form of finished pharmaceutical products (FPPs).
Indar was created under a resolution of the Cabinet of Ministers in 1997 under the aegis of Kyiv meat processing plant. In 2012, the state fully reinstated its control over the enterprise which it lost in 2008 when the state stake of 70.7% belonging to Ukrmedprom was sold to Storke Holdings Limited (Belize).
Indar in 2016 joined the Association Manufactures of Medications of Ukraine (AMMU).
KYIV. March 21 (Interfax-Ukraine) – India’s Dr.Reddy’s integrated international pharmaceutical company is still optimistic about the Ukrainian pharmaceutical market. The company continues developing its Ukrainian business, Dr.Reddy’s Executive Vice President M.V. Ramana has said.
“Ukraine is a key market that Dr.Reddy’s is focusing on,” he told Interfax-Ukraine.
Commenting on the company’s operation in Ukraine in 2015, Ramana said that the economic turmoil has had a direct impact on the company’s business. General slow on the Ukrainian pharmaceutical market and a decline in buying power have made a serious gap in the company’s efficiency.
He said that hryvnia devaluation had the worst aftermath for the business.
“Nevertheless, despite the worsening of the situation with national currency devaluation, Dr.Reddy’s is among few global companies operating in Ukraine that tried to ensure the affordability of its products. This is the key goal of our company,” he said.
Ramana said that Dr.Reddy’s was one of few companies that continued their operation in eastern Ukraine, in Donetsk and Luhansk regions, at the beginning of the conflict in May-June 2014. Dr.Reddy’s team in the region continued providing for the needs of patients and healthcare centers.
“After the worsening of the conflict in the region in 2015… Dr.Reddy’s helped most of its employees move to other regions of Ukraine,” he said.
Being optimistic about the Ukrainian pharmaceutical market, Dr.Reddy’s will continue investing funds in innovation and affordable medicines and will focus its attention to business growth, he said.
Ramana said that the potential of the Ukrainian market is still large, and the current crisis is a temporary regress that could last from 18 to 24 months.
Dr.Reddy’s developed several brands of prescription, Over-the-Counter (OTC) and anti-cancer drugs. They are leaders in their market segments.
Ramana said that Dr.Reddy’s now is ninth among top 10 leading foreign companies operating in Ukraine.
He said that Dr.Reddy’s will continue enlarging its presence in Ukraine, bringing innovation products of great demand to the Ukrainian market.
